JK BioPharma Solutions Form 3/A NeuroBo Pharmaceuticals / Sun Dae Kang ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

JK BioPharma Solutions, Inc

(Last) (First) (Middle)

1 RESEARCH COURT, SUITE 370

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/30/2019

3. Issuer Name and Ticker or Trading Symbol
NeuroBo Pharmaceuticals, Inc. [ NRBO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)
01/09/2020

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,817,842	D(1)
Common Stock	800,170	D(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

JK BioPharma Solutions, Inc

(Last) (First) (Middle)

1 RESEARCH COURT, SUITE 370

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Kang Sun Dae

(Last) (First) (Middle)

1 RESEARCH COURT, SUITE 370

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

Explanation of Responses:

1. These shares are owned directly by JK BioPharma Solutions, Inc., a 10% owner of the Issuer, and indirectly by Dr. Sun Dae Kang, as director of JK BioPharma Solutions, Inc. Dr. Kang disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

2. These shares are owned directly by Dr. Sun Dae Kang.

Remarks:

This Form 3 is being amended to add Sun Dae Kang as a Reporting Person. Exhibit 24.1 - Power of Attorney.

	/s/ JK BioPharma Solutions, Inc. By: Jeong Gyun Oh, President and CEO	01/15/2020
	/s/ Sun Dae Kang	01/15/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.